Výsledky vyhledávání - "Courtney Vito"

Abstract P5-22-12: Oncological safety of nipple-areola sparing mastectomy in comparison with skin sparing and total mastectomy: Results from a NCI-designated comprehensive cancer center

Autor: Joyce C. Niland, Veronica Jones, Lesley Taylor, X Wang, Lily L. Lai, L Springer, Laura Kruper, Rebecca A. Ottesen, J Nikowitz, Z Bostanci, Isaac Benjamin Paz, John H. Yim, Courtney Vito

Publikováno v: Cancer Research. 78:P5-22

Nipple-areola sparing mastectomy (NSM) may be offered to some women with breast cancer as an alternative to skin sparing (SSM) or total mastectomy (TM) with excellent cosmetic results and acceptable recurrence risk. The aim of this study is to determ

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8a6a89cc69d444d630c361c8023344aa
https://doi.org/10.1158/1538-7445.sabcs17-p5-22-12

Zobrazit plný text záznamu

Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant

Autor: Joanne E. Mortimer, Karineh Petrossian, Noriko Kanaya, Daniel Schmolze, Pei Yin Hsu, Hannah Lu, Duc Nguyen, Shiuan Chen, Laura Kruper, Peiguo Chu, Victoria Shang Wu, Chunyu Liu, Courtney Vito, Hang Kai Hsu, Masaya Kai

Publikováno v: Clinical Cancer Research. 24:395-406

Purpose: Therapeutic strategies against hormonal receptor–positive (HR+)/HER2+ breast cancers with poor response to trastuzumab need to be optimized. Experimental Design: Two HR+/HER2+ patient-derived xenograft (PDX) models named as COH-SC1 and COH

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::eb4b9316c28bbad5807e05de68386f2a
https://doi.org/10.1158/1078-0432.ccr-17-1983

Zobrazit plný text záznamu

Time to Treatment: Measuring Quality Breast Cancer Care

Autor: Emily Marcinkowski, Laura Kruper, Joanne E. Mortimer, Amy C. Polverini, Courtney Vito, Rebecca A. Nelson, Lesley Taylor, Lily L. Lai, John H. Yim, Veronica Jones

Publikováno v: Annals of Surgical Oncology. 23:3392-3402

To optimize breast cancer care, several organizations have crafted guidelines to define best practices for treating breast cancer. In addition to recommended therapies, 'timeliness of treatment' has been proposed as a quality metric. Our study evalua

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::507bf13edc769ae6943b8735678e563a
https://doi.org/10.1245/s10434-016-5486-7

Zobrazit plný text záznamu

Abstract P1-14-10: Phase II trial of neoadjuvant chemotherapy with carboplatin and nab-paclitaxel in patients with triple negative locally advanced and inflammatory breast cancer

Autor: Joanne E. Mortimer, Arti Hurria, Lesley Taylor, S. Koehler, Tommy Tong, Courtney Vito, Kim Robinson, Y Yuan, George Somlo, James Waisman, Samuel Chung, John H. Yim, Benjamin Paz, Laura Kruper, Christina Yeon, Paul Frankel

Publikováno v: Cancer Research. 76:P1-14

Background: Pathologic complete response (pCR) and residual cancer burden (RCB scores of 0 [pCR] or 1[near CR]) after neoadjuvant chemotherapy (NCT) may predict for improved survival (Symmans et al. J Clin Oncol 25:4414-22, 2007). We set out to test

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::11c6fee5fa9a325978d850cceaaf9aca
https://doi.org/10.1158/1538-7445.sabcs15-p1-14-10

Zobrazit plný text záznamu

Abstract A084: The forgotten race: Under-representation of Asians in clinical research

Publikováno v: Cancer Epidemiology, Biomarkers & Prevention. 29:A084-A084

The United States (US) is racially and culturally diverse. Still, white women disproportionately comprise clinical trial participants, stemming largely from the fact that minorities often decline participation. Clinical trial findings, therefore, hav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a43e45884faf2296fbecd4b9cefd361
https://doi.org/10.1158/1538-7755.disp18-a084

Zobrazit plný text záznamu

Abstract B109: Architecture of increased breast cancer risk

Publikováno v: Cancer Epidemiology, Biomarkers & Prevention. 29:B109-B109

Purpose: To highlight the importance of building a high-risk breast cancer clinic for women who do not have a BRCA 1, BRCA 2 or other highly penetrant cancer susceptibility mutation. Background: Breast cancer is the most common cancer in women and th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::83becd04bcbf95a36adcc4be945b1c61
https://doi.org/10.1158/1538-7755.disp18-b109

Zobrazit plný text záznamu

Abstract P6-11-09: A preclinical study to demonstrate the utility of fulvestrant and MLN0128 combination against HR+ and HER2+ breast cancer

Autor: Joanne E. Mortimer, Masaya Kai, Courtney Vito, Shang Victoria Wu, Shiuan Chen, Thenhang Luu, Noriko Kanaya, Hannah Lu, Laura Kruper

Publikováno v: Cancer Research. 75:P6-11

Background: Up to 10% of total breast cancers are positive for both hormone receptor [HR: estrogen receptor (ER) and/or progesterone receptor (PR)] and HER2. These patients belong mainly to the luminal B subtype, which exhibits resistance to endocrin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95eed45c95ee33b6251c64f11d0583b4
https://doi.org/10.1158/1538-7445.sabcs14-p6-11-09

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání